Amivantamab (JNJ-61186372) is a bispecific monoclonal that targets EGFR and MET [1
]. Examination of binding by surface plasmon resonance confirms that JNJ-61186372 can bind to EGFR and MET simultaneously [1
]. JNJ-61186372 binding inhibits phosphorylation of both of the target receptor tyrosine kinases in vitro
. Tackling the tyrosine kinases from outside the cell is hypothesised to override the issue of treatment resistance due to kinase mutations that frequently arise during therapy with intracellulary-acting small molecule kinase inhibitors [2
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.